| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-01-13 | UCB (Belgium) | nomination |
Nomination | |||
| 2015-01-13 | Fedora Pharmaceuticals (Canada) Meiji Seika Pharma (Japan) Roche (Switzerland) | OP0595 | development licensing commercialisation |
Infectious diseases | Licensing agreement | |
| 2015-01-13 | Antitope, an Abzena company (UK) ANRS (France) Inserm (France) The Baylor Institute for Immunology Research (USA - TX) | cell lines for GMP manufacture of two anti-CD40-HIV fusion proteins | HIV infection | collaboration |
Infectious diseases | Collaboration agreement |
| 2015-01-13 | CiToxLAB (France) | nomination |
Technology - Services | Nomination | ||
| 2015-01-13 | BMS (USA - NY) Eli Lilly (USA - IN) | Opdivo® (nivolumab), galunisertib (LY2157299) | advanced (metastatic and/or unresectable) glioblastoma, hepatocellular carcinoma, non-small cell lung cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-01-13 | Medday (France) | nomination |
Autoimmune diseases - Neurodegenerative diseases - Neurological diseases - Rare diseases | Nomination | ||
| 2015-01-13 | Vedanta Biosciences (USA - MA) Janssen Biotech, a J&J company (USA - NJ) | VE202 | inflammatory bowel disease | licensing |
Autoimmune diseases - Inflammatory diseases - Digestive diseases | Licensing agreement |
| 2015-01-13 | Moderna Therapeutics (USA - MA) Merck&Co (USA - NJ) | mRNA-based treatments and vaccines | four undisclosed viral diseases | licensing collaboration |
Infectious diseases | Licensing agreement |
| 2015-01-12 | Tokai Pharmaceuticals (USA - MA) Johns Hopkins University (USA - MD) | companion diagnostic to determine the AR-V7 status of patients with castration-resistant prostate cancer (CRPC) for use with galeterone | castration-resistant prostate cancer | development licensing |
Cancer - Oncology - Diagnostic | Development agreement |
| 2015-01-12 | Tokai Pharmaceuticals (USA - MA) Qiagen (The Netherlands) | companion diagnostic to determine the AR-V7 status of patients with castration-resistant prostate cancer (CRPC) for use with galeterone | castration-resistant prostate cancer | development |
Cancer - Oncology - Diagnostic | Development agreement |
| 2015-01-12 | Dako (Denmark) Cell Signaling Technology (USA - MA) | antibodies for use in Dako-branded companion diagnostics products | collaboration |
Diagnostic | Collaboration agreement | |
| 2015-01-12 | Ariana Pharma (France) Nabsys (USA - RI) | DNA structural variants linked to prostate and breast cancers | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2015-01-12 | Amgen (USA - CA) The University of Texas MD Anderson Cancer Center (USA - TX) | bispecific T cell engager (BiTE®) antibody constructs | myelodysplastic syndrome | R&D |
Cancer - Oncology | R&D agreement |
| 2015-01-12 | Neostem (USA - NY) Invetech (USA - CA) | closed processing system for cell therapy manufacturing | development |
Technology - Services | Development agreement | |
| 2015-01-12 | Argen-X (Belgium) de Duve Institute (Université Catholique de Louvain - Belgium) | SIMPLE Antibody™ platform | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2015-01-12 | Novartis (Switzerland) Debiopharm (Switzerland) | alisporivir (DEB025) | hepatitis C | Infectious diseases | Termination of the agreement | |
| 2015-01-12 | Roche (Switzerland) Foundation Medicine (USA - MA) | genomic profile tests for cancer immunotherapies and for continuous blood-based monitoring | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2015-01-12 | AC Immune (Switzerland) Janssen Pharmaceuticals, a J&J company (USA - NJ) | therapeutic anti-Tau vaccines including ACI-35 | Alzheimer’s disease and potentially other tauopathies | R&D licensing |
Neurodegenerative diseases | Licensing agreement |
| 2015-01-12 | CTI Biopharma - previously known as Cell Therapeutics (USA - WA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-01-12 | METAFORA biosystems (France) Ozyme (France) | METAscreen® kits | distribution |
Technology - Services | Distribution agreement |
